VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CCM
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
CCMConcord Medical Services Holdings Limited
$4.80$698952
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. CCM
  4. Financial Ratios

Concord Medical Services Holdings Limited (CCM) Financial Ratios

Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -5.4%. (2008–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

CCM Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$698952$562074$783328$2M$2M$3M$4M$4M$5M$5M$7M
Enterprise Value$491M$3.3B$3.7B$3.2B$3.1B$2.6B$2.0B$1.5B$539M$1.1B$1.0B
P/E Ratio →-0.05——————————
P/S Ratio0.010.000.000.000.010.010.020.020.030.010.01
P/B Ratio0.000.000.000.000.000.000.000.000.000.000.01
P/FCF———————————
P/OCF—————————0.18—

P/E links to full P/E history page with 30-year chart

CCM EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—7.259.686.036.535.319.077.332.823.472.21
EV / EBITDA———————————
EV / EBIT———————————
EV / FCF———————————

CCM Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin5.6%5.6%-20.6%-14.3%-32.3%-11.7%5.9%-8.0%10.4%29.6%37.0%
Operating Margin-52.0%-52.0%-138.6%-86.2%-111.2%-94.4%-141.7%-220.5%-156.8%-64.0%-37.1%
Net Profit Margin-20.2%-20.2%-80.3%-55.4%-103.7%-55.9%-139.0%-154.8%-123.0%-85.9%-57.5%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE-5.4%-5.4%-18.3%-15.8%-20.6%-10.6%-14.5%-14.8%-14.3%-25.3%-19.6%
ROA-1.4%-1.4%-4.8%-4.9%-8.0%-4.7%-6.4%-6.9%-5.8%-8.5%-7.7%
ROIC-3.4%-3.4%-7.7%-6.9%-7.6%-7.1%-6.1%-10.7%-9.0%-7.2%-5.4%
ROCE-5.2%-5.2%-12.2%-10.3%-10.2%-8.9%-7.4%-11.8%-9.9%-9.1%-7.4%

CCM Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity1.961.962.431.891.611.000.980.810.411.220.97
Debt / EBITDA———————————
Net Debt / Equity—1.802.301.851.530.940.840.770.231.130.81
Net Debt / EBITDA———————————
Debt / FCF———————————
Interest Coverage-1.45-1.45-2.47-2.79-4.36-6.21-3.78-12.59-6.36-2.04-1.20

CCM Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio0.480.480.460.320.680.731.320.451.411.001.26
Quick Ratio0.460.460.450.300.600.681.280.441.411.001.25
Cash Ratio0.150.150.170.030.140.200.650.120.520.090.20
Asset Turnover—0.070.060.090.080.080.040.050.040.100.14
Inventory Turnover9.469.4613.8515.227.3614.259.7149.3450.9937.0748.38
Days Sales Outstanding—34.9148.6449.92100.72287.89307.96222.92388.32326.78241.48

CCM Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield——————————100.0%
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield———————————
FCF Yield———————————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%100.0%
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%100.0%
Shares Outstanding—$145615$145600$145600$145600$145600$145600$144700$144566$144533$145133

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Regulatory and Solvency Risk

Distress Discount Reflects Structural Impairment

Based on reported figures, CCM trades at a price-to-sales multiple of 0.01, a valuation level that suggests the market has largely abandoned expectations for a return to profitability or meaningful growth in the company's specialized oncology network and high-end hospital service segments in China.

The current valuation multiples appear to reflect a deep distress discount rather than a growth-oriented pricing model. Investors should monitor whether this low valuation is a temporary market overreaction or a rational response to the persistent negative operating margins and the lack of a clear path toward positive earnings.

Capital Compounding Remains Fundamentally Negative

As reported in financial statements, CCM's ROIC has remained consistently negative, hovering around -1.0% in 2025Q2, which indicates that the company is currently destroying shareholder value rather than compounding it through its heavy investments in radiotherapy equipment and specialized oncology facilities.

The inability to generate positive returns on invested capital suggests that the company's asset-heavy strategy is failing to achieve the necessary utilization rates to cover its high depreciation and operating costs. This trend warrants further investigation into whether the company's core assets are becoming obsolete or if the regulatory environment has permanently impaired their earning potential.

Working Capital Cycles Signal Inefficiency

According to recent SEC filings, CCM's cash conversion cycle has fluctuated significantly, reaching -35 days in 2025Q2, a metric that appears to be driven more by extended payment terms to suppliers rather than operational efficiency in collecting receivables from its partner public hospitals.

The reliance on stretching accounts payable to manage liquidity may indicate strained relationships with suppliers or a lack of bargaining power in the current market. Analysts should interpret these efficiency metrics with caution, as they may mask underlying difficulties in converting service delivery into actual cash inflows.

Debt Burden Exceeds Equity Base

Based on reported figures, CCM's debt-to-equity ratio has reached 2.22 as of 2025Q2, a level that highlights the company's precarious financial position as its equity base continues to erode due to persistent net losses and the absence of positive operating cash flow generation.

The company's reliance on debt to fund its capital-intensive operations appears increasingly unsustainable given the lack of interest coverage. Investors should monitor the company's ability to refinance existing obligations, as the current leverage profile leaves little room for error in a tightening regulatory and credit environment.

Misapplication of Traditional Hospital Multiples

As indicated by the data, the market's common use of P/E ratios to evaluate CCM is fundamentally flawed, as the company's persistent negative earnings and high depreciation charges render traditional valuation metrics meaningless for assessing its true underlying value as a specialized medical infrastructure provider.

Instead of P/E, analysts should focus on asset-based valuation or adjusted EBITDA metrics that account for the specific lifecycle of radiotherapy equipment. Relying on standard healthcare multiples obscures the reality that CCM is currently an infrastructure-heavy play facing significant regulatory headwinds rather than a traditional, cash-generative hospital operator.

Download Financial Ratios Data

Includes 30+ ratios · 18 years · Updated daily

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

CCM — Frequently Asked Questions

Quick answers to the most common questions about buying CCM stock.

What is Concord Medical Services Holdings Limited's P/E ratio?

Concord Medical Services Holdings Limited's current P/E ratio is -0.1x. The historical average is 0.9x.

What is Concord Medical Services Holdings Limited's ROE?

Concord Medical Services Holdings Limited's return on equity (ROE) is -5.4%. The historical average is -7.2%.

Is CCM stock overvalued?

Based on historical data, Concord Medical Services Holdings Limited is trading at a P/E of -0.1x. Compare with industry peers and growth rates for a complete picture.

What are Concord Medical Services Holdings Limited's profit margins?

Concord Medical Services Holdings Limited has 5.6% gross margin and -52.0% operating margin.